CIMZIA (certolizumab pegol) for injection, for subcutaneous use

UCB

CIMZIA is a tumor necrosis factor (TNF) blocker indicated for:

• Reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
• Treatment of adults with moderately to severely active rheumatoid arthritis
• Treatment of adult patients with active psoriatic arthritis.
• Treatment of adults with active ankylosing spondylitis
• Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation
• Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

• Refrigerate intact carton at 2° to 8° C (36° to 46° F). Do not freeze. Do not separate contents of carton prior to use. Do not use beyond expiration date, which is located on the drug label and carton.
• Protect solution from light.